341 related articles for article (PubMed ID: 25164658)
1. Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice.
Jacobsen H; Ozmen L; Caruso A; Narquizian R; Hilpert H; Jacobsen B; Terwel D; Tanghe A; Bohrmann B
J Neurosci; 2014 Aug; 34(35):11621-30. PubMed ID: 25164658
[TBL] [Abstract][Full Text] [Related]
2. Passive immunotherapy with a novel antibody against 3pE-modified Aβ demonstrates potential for enhanced efficacy and favorable safety in combination with BACE inhibitor treatment in plaque-depositing mice.
Janssens J; Hermans B; Vandermeeren M; Barale-Thomas E; Borgers M; Willems R; Meulders G; Wintmolders C; Van den Bulck D; Bottelbergs A; Ver Donck L; Larsen P; Moechars D; Edwards W; Mercken M; Van Broeck B
Neurobiol Dis; 2021 Jul; 154():105365. PubMed ID: 33848635
[TBL] [Abstract][Full Text] [Related]
3. Antibody-Based In Vivo PET Imaging Detects Amyloid-β Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition.
Meier SR; Syvänen S; Hultqvist G; Fang XT; Roshanbin S; Lannfelt L; Neumann U; Sehlin D
J Nucl Med; 2018 Dec; 59(12):1885-1891. PubMed ID: 29853653
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of chronic BACE1 inhibition in PS2APP mice depends on the regional Aβ deposition rate and plaque burden at treatment initiation.
Brendel M; Jaworska A; Overhoff F; Blume T; Probst F; Gildehaus FJ; Bartenstein P; Haass C; Bohrmann B; Herms J; Willem M; Rominger A
Theranostics; 2018; 8(18):4957-4968. PubMed ID: 30429879
[TBL] [Abstract][Full Text] [Related]
5. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
Neumann U; Rueeger H; Machauer R; Veenstra SJ; Lueoend RM; Tintelnot-Blomley M; Laue G; Beltz K; Vogg B; Schmid P; Frieauff W; Shimshek DR; Staufenbiel M; Jacobson LH
Mol Neurodegener; 2015 Sep; 10():44. PubMed ID: 26336937
[TBL] [Abstract][Full Text] [Related]
6. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
7. Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS.
Georgievska B; Gustavsson S; Lundkvist J; Neelissen J; Eketjäll S; Ramberg V; Bueters T; Agerman K; Juréus A; Svensson S; Berg S; Fälting J; Lendahl U
J Neurochem; 2015 Feb; 132(4):477-86. PubMed ID: 25156639
[TBL] [Abstract][Full Text] [Related]
8. Effects of TNFalpha-converting enzyme inhibition on amyloid beta production and APP processing in vitro and in vivo.
Kim ML; Zhang B; Mills IP; Milla ME; Brunden KR; Lee VM
J Neurosci; 2008 Nov; 28(46):12052-61. PubMed ID: 19005070
[TBL] [Abstract][Full Text] [Related]
9. AZ-4217: a high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice.
Eketjäll S; Janson J; Jeppsson F; Svanhagen A; Kolmodin K; Gustavsson S; Radesäter AC; Eliason K; Briem S; Appelkvist P; Niva C; Berg AL; Karlström S; Swahn BM; Fälting J
J Neurosci; 2013 Jun; 33(24):10075-84. PubMed ID: 23761903
[TBL] [Abstract][Full Text] [Related]
10. Icariin decreases the expression of APP and BACE-1 and reduces the β-amyloid burden in an APP transgenic mouse model of Alzheimer's disease.
Zhang L; Shen C; Chu J; Zhang R; Li Y; Li L
Int J Biol Sci; 2014; 10(2):181-91. PubMed ID: 24550686
[TBL] [Abstract][Full Text] [Related]
11. Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease.
Paris D; Ganey NJ; Laporte V; Patel NS; Beaulieu-Abdelahad D; Bachmeier C; March A; Ait-Ghezala G; Mullan MJ
J Neuroinflammation; 2010 Mar; 7():17. PubMed ID: 20211007
[TBL] [Abstract][Full Text] [Related]
12. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.
Roberds SL; Anderson J; Basi G; Bienkowski MJ; Branstetter DG; Chen KS; Freedman SB; Frigon NL; Games D; Hu K; Johnson-Wood K; Kappenman KE; Kawabe TT; Kola I; Kuehn R; Lee M; Liu W; Motter R; Nichols NF; Power M; Robertson DW; Schenk D; Schoor M; Shopp GM; Shuck ME; Sinha S; Svensson KA; Tatsuno G; Tintrup H; Wijsman J; Wright S; McConlogue L
Hum Mol Genet; 2001 Jun; 10(12):1317-24. PubMed ID: 11406613
[TBL] [Abstract][Full Text] [Related]
13. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients.
Li R; Lindholm K; Yang LB; Yue X; Citron M; Yan R; Beach T; Sue L; Sabbagh M; Cai H; Wong P; Price D; Shen Y
Proc Natl Acad Sci U S A; 2004 Mar; 101(10):3632-7. PubMed ID: 14978286
[TBL] [Abstract][Full Text] [Related]
14. BACE-1 inhibition prevents the γ-secretase inhibitor evoked Aβ rise in human neuroblastoma SH-SY5Y cells.
Jämsä A; Belda O; Edlund M; Lindström E
J Biomed Sci; 2011 Oct; 18(1):76. PubMed ID: 22018341
[TBL] [Abstract][Full Text] [Related]
15. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β.
Bohrmann B; Baumann K; Benz J; Gerber F; Huber W; Knoflach F; Messer J; Oroszlan K; Rauchenberger R; Richter WF; Rothe C; Urban M; Bardroff M; Winter M; Nordstedt C; Loetscher H
J Alzheimers Dis; 2012; 28(1):49-69. PubMed ID: 21955818
[TBL] [Abstract][Full Text] [Related]
16. Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition.
Schelle J; Häsler LM; Göpfert JC; Joos TO; Vanderstichele H; Stoops E; Mandelkow EM; Neumann U; Shimshek DR; Staufenbiel M; Jucker M; Kaeser SA
Alzheimers Dement; 2017 Jun; 13(6):701-709. PubMed ID: 27750032
[TBL] [Abstract][Full Text] [Related]
17. The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.
Hook G; Hook V; Kindy M
J Alzheimers Dis; 2011; 26(2):387-408. PubMed ID: 21613740
[TBL] [Abstract][Full Text] [Related]
18. Gleevec shifts APP processing from a β-cleavage to a nonamyloidogenic cleavage.
Netzer WJ; Bettayeb K; Sinha SC; Flajolet M; Greengard P; Bustos V
Proc Natl Acad Sci U S A; 2017 Feb; 114(6):1389-1394. PubMed ID: 28115709
[TBL] [Abstract][Full Text] [Related]
19. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
[TBL] [Abstract][Full Text] [Related]
20. BACE overexpression alters the subcellular processing of APP and inhibits Abeta deposition in vivo.
Lee EB; Zhang B; Liu K; Greenbaum EA; Doms RW; Trojanowski JQ; Lee VM
J Cell Biol; 2005 Jan; 168(2):291-302. PubMed ID: 15642747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
